#United States #New York #Securities Fraud #Pomerantz Law Firm #Acadia Pharmaceuticals

Pomerantz Law Firm Investigates Acadia Pharmaceuticals for Investor Claims

On October 18, 2025, Pomerantz LLP, recognized as a top law firm specializing in corporate, securities, and antitrust class litigation, announced an investigation into claims from investors of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). The inquiry centers around possible securities fraud and other illegal business practices by Acadia and some of its officers and directors.

The scrutiny arises following a disheartening announcement from Acadia regarding the results of its Phase 3 COMPASS clinical trial. This trial was aimed at determining the efficacy and safety of intranasal carbetocin (ACP-101) for patients with hyperphagia, a condition frequently associated with Prader-Willi syndrome (PWS). On September 24, 2025, Acadia released a statement detailing that the drug did not show a statistically significant improvement compared to placebo on its primary endpoint. Furthermore, there was no separation from placebo on any of the secondary endpoints, leading Acadia's Head of Research and Development to declare that they would not pursue further investigation into intranasal carbetocin given these results.

The announcement triggered a significant decline in Acadia’s stock prices, which fell by $2.34, equating to a staggering 9.92% drop, closing at $21.26 per share on the same day. This sharp decline raised alarm bells for investors, prompting the investigation by Pomerantz LLP, which is known for its robust history of representing victims of securities mismanagement and corporate misconduct.

Founded over 85 years ago by the late Abraham L. Pomerantz, the firm has secured numerous multimillion-dollar awards for class members affected by corporate malfeasance. Staying true to its legacy, Pomerantz continues to champion the rights of investors, holding corporations accountable for dishonest practices. Pomerantz encourages affected investors to reach out directly to Danielle Peyton for inquiries about joining the class action lawsuit.

For more information about joining this class action, contact Danielle Peyton at Pomerantz LLP via email at [email protected] or call 646-581-9980, ext. 7980. This investigation is vital for safeguarding investors' rights and ensuring that corporations adhere to fair and transparent business practices.

This case underlines the importance of vigilance and accountability in the pharmaceutical industry, particularly as companies navigate complex regulatory landscapes while striving to innovate and meet medical needs. As investors, understanding the business decisions and outcomes is crucial in making informed decisions moving forward. Acadia Pharmaceuticals, with its keen focus on rare diseases and conditions, will be under close watch as it confronts these challenges and strives to regain its footing in the biotech marketplace. Investors and stakeholders alike will be awaiting any further developments as Pomerantz continues its investigation into this unfolding situation.